A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure.
Ammeti D, Marzollo A, Gabelli M, Zanchetta ME, Tretti-Parenzan C, Bottega R, Capaci V, Biffi A, Savoia A, Bresolin S, Faleschini M.

Perinatal-lethal nonimmune fetal hydrops attributed to MECOM-associated bone marrow failure.
Dash CA, Madden JA, Cummings C, Rose M, Wilson SD, Mori M, Agrawal PB, Chaudhari BP, Wojcik MH., Free PMC Article

MECOM Deficiency: from Bone Marrow Failure to Impaired B-Cell Development.
Voit RA, Sankaran VG.

Expanded phenotypic and hematologic abnormalities beyond bone marrow failure in MECOM-associated syndromes.
Lozano Chinga MM, Bertuch AA, Afify Z, Dollerschell K, Hsu JI, John TD, Rao ES, Rowe RG, Sankaran VG, Shimamura A, Williams DA, Nakano TA.,

Epigenetic landscape reveals MECOM as an endothelial lineage regulator.
Lv J, Meng S, Gu Q, Zheng R, Gao X, Kim JD, Chen M, Xia B, Zuo Y, Zhu S, Zhao D, Li Y, Wang G, Wang X, Meng Q, Cao Q, Cooke JP, Fang L, Chen K, Zhang L., Free PMC Article

EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, Bando M, Shirahige K, Kurokawa M., Free PMC Article

The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX, Pan XA, Gao MG, Kong J, Jiang H, Chang YJ, Zhang XH, Wang Y, Liu KY, Chen Z, Zhao XS, Huang XJ.

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.
Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, Kern W, Haferlach C., Free PMC Article

EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells.
Vinothkumar K, Chanda S, Singh VK, Biswas S, Mohapatra S, Biswas G, Chakraborty S.

Mapping the developing human cardiac endothelium at single-cell resolution identifies MECOM as a regulator of arteriovenous gene expression.
McCracken IR, Dobie R, Bennett M, Passi R, Beqqali A, Henderson NC, Mountford JC, Riley PR, Ponting CP, Smart N, Brittan M, Baker AH., Free PMC Article

MECOM-related disorder: Radioulnar synostosis without hematological aberration due to unique variants.
Shen F, Yang Y, Zheng Y, Li P, Luo Z, Fu Y, Zhu G, Mei H, Chen S, Zhu Y.

EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells.
Grandits AM, Bromberger S, Heller G, Reinoehl BA, Tomasich E, Schossleitner K, Berghoff AS, Fuereder T, Wieser R., Free PMC Article

MECOM gene overexpression in pediatric patients with acute myeloid leukemia.
Elsherif M, Hammad M, Hafez H, Yassin D, Ashraf M, Yasser N, Lehmann L, Elhaddad A.

Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, Chen Q, Chen YH, Lu X, Jennings L, Frankfurt O, Altman J, Sukhanova M.

EVI1 overexpression promotes ovarian cancer progression by regulating estrogen signaling.
Wang Z, Li Y, Wang N, Li P, Kong B, Liu Z.

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN., Free PMC Article

Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S, Rafiee MR, Bakr A, Mika J, Kruse S, Müller J, Schweiggert S, Herrmann C, Sigismondo G, Schmezer P, Krijgsveld J, Gröschel S., Free PMC Article

The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S, Mulet-Lazaro R, Erpelinck-Verschueren C, van Herk S, Havermans M, Arricibita Varea A, Vermeulen M, Beverloo HB, Gröschel S, Haferlach T, Haferlach C, J Wouters B, Bindels E, Smeenk L, Delwel R., Free PMC Article

EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
Paredes R, Schneider M, Pearson S, Teng HY, Kelly JR, Pierce A, Somervaille TCP, Whetton AD, Meyer S., Free PMC Article

PAX8 and MECOM are interaction partners driving ovarian cancer.
Bleu M, Mermet-Meillon F, Apfel V, Barys L, Holzer L, Bachmann Salvy M, Lopes R, Amorim Monteiro Barbosa I, Delmas C, Hinniger A, Chau S, Kaufmann M, Haenni S, Berneiser K, Wahle M, Moravec I, Vissières A, Poetsch T, Ahrné E, Carte N, Voshol J, Bechter E, Hamon J, Meyerhofer M, Erdmann D, Fischer M, Stachyra T, Freuler F, Gutmann S, Fernández C, Schmelzle T, Naumann U, Roma G, Lawrenson K, Nieto-Oberhuber C, Cobos-Correa A, Ferretti S, Schübeler D, Galli GG., Free PMC Article

EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
Paredes R, Kelly JR, Geary B, Almarzouq B, Schneider M, Pearson S, Narayanan P, Williamson A, Lovell SC, Wiseman DH, Chadwick JA, Jones NJ, Kustikova O, Schambach A, Garner T, Amaral FMR, Pierce A, Stevens A, Somervaille TCP, Whetton AD, Meyer S., Free PMC Article

EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, Ogoh H, Matsuo H, Adachi S, Taga T, Tomizawa D, Osato M, Soga T, Morishita K, Moritake H., Free PMC Article

Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count.
Summerer I, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A.

Evi-1 Influence on Clinical Progress of Colorectal Cancer Patients.
Zhu Y, Zhang J, Ye Z, Peng P, Lan X, Xie L, Qin M, Huang J.

Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Ottema S, Mulet-Lazaro R, Beverloo HB, Erpelinck C, van Herk S, van der Helm R, Havermans M, Grob T, Valk PJM, Bindels E, Haferlach T, Haferlach C, Smeenk L, Delwel R.